Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1997 1
2003 1
2004 3
2006 4
2007 4
2008 1
2009 2
2010 2
2011 3
2012 4
2013 3
2014 3
2015 3
2016 2
2017 1
2018 1
2019 8
2020 4
2021 4
2022 8
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Results by year

Filters applied: . Clear all
Page 1
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, Gillessen S, Cook A, Brawley C, Amos CL, Atako N, Pugh C, Buckner M, Chowdhury S, Malik Z, Russell JM, Gilson C, Rush H, Bowen J, Lydon A, Pedley I, O'Sullivan JM, Birtle A, Gale J, Srihari N, Thomas C, Tanguay J, Wagstaff J, Das P, Gray E, Alzoueb M, Parikh O, Robinson A, Syndikus I, Wylie J, Zarkar A, Thalmann G, de Bono JS, Dearnaley DP, Mason MD, Gilbert D, Langley RE, Millman R, Matheson D, Sydes MR, Brown LC, Parmar MKB, James ND; Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. Attard G, et al. Lancet. 2022 Jan 29;399(10323):447-460. doi: 10.1016/S0140-6736(21)02437-5. Epub 2021 Dec 23. Lancet. 2022. PMID: 34953525 Free PMC article.
There was no evidence of a difference in metatasis-free survival when enzalutamide and abiraterone acetate were administered concurrently compared with abiraterone acetate alone (interaction HR 1.02, 0.70-1.50, p=0.91) and no evidence of between-trial heterogeneity (I(2) …
There was no evidence of a difference in metatasis-free survival when enzalutamide and abiraterone acetate were administered concurrently co …
Intravenous Doxycycline, Azithromycin, or Both for Severe Scrub Typhus.
Varghese GM, Dayanand D, Gunasekaran K, Kundu D, Wyawahare M, Sharma N, Chaudhry D, Mahajan SK, Saravu K, Aruldhas BW, Mathew BS, Nair RG, Newbigging N, Mathew A, Abhilash KPP, Biswal M, Prasad AH, Zachariah A, Iyadurai R, Hansdak SG, Sathyendra S, Sudarsanam TD, Prakash JAJ, Manesh A, Mohan A, Tarning J, Blacksell SD, Peerawaranun P, Waithira N, Mukaka M, Cheah PY, Peter JV, Abraham OC, Day NPJ; INTREST Trial Investigators. Varghese GM, et al. N Engl J Med. 2023 Mar 2;388(9):792-803. doi: 10.1056/NEJMoa2208449. N Engl J Med. 2023. PMID: 36856615 Free PMC article. Clinical Trial.
The use of combination therapy resulted in a lower incidence of the composite primary outcome than the use of doxycycline (33% and 47%, respectively), for a risk difference of -13.3 percentage points (95% confidence interval [CI], -21.6 to -5.1; P = 0.002). The incidence w …
The use of combination therapy resulted in a lower incidence of the composite primary outcome than the use of doxycycline (33% and 47%, resp …
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
Attard G, Murphy L, Clarke NW, Sachdeva A, Jones C, Hoyle A, Cross W, Jones RJ, Parker CC, Gillessen S, Cook A, Brawley C, Gilson C, Rush H, Abdel-Aty H, Amos CL, Murphy C, Chowdhury S, Malik Z, Russell JM, Parkar N, Pugh C, Diaz-Montana C, Pezaro C, Grant W, Saxby H, Pedley I, O'Sullivan JM, Birtle A, Gale J, Srihari N, Thomas C, Tanguay J, Wagstaff J, Das P, Gray E, Alzouebi M, Parikh O, Robinson A, Montazeri AH, Wylie J, Zarkar A, Cathomas R, Brown MD, Jain Y, Dearnaley DP, Mason MD, Gilbert D, Langley RE, Millman R, Matheson D, Sydes MR, Brown LC, Parmar MKB, James ND; STAMPEDE investigators. Attard G, et al. Lancet Oncol. 2023 May;24(5):443-456. doi: 10.1016/S1470-2045(23)00148-1. Lancet Oncol. 2023. PMID: 37142371 Free article.
In the abiraterone trial, median overall survival was 76.6 months (95% CI 67.8-86.9) in the abiraterone group versus 45.7 months (41.6-52.0) in the standard of care group (hazard ratio [HR] 0.62 [95% CI 0.53-0.73]; p<0.0001). In the abiraterone and enzalutamide trial, m …
In the abiraterone trial, median overall survival was 76.6 months (95% CI 67.8-86.9) in the abiraterone group versus 45.7 months (41.6-52.0) …
High-fidelity, simulation-based microsurgical training for neurosurgical residents.
Santyr B, Abbass M, Chalil A, Vivekanandan A, Krivosheya D, Denning LM, Mattingly TK, Haji FA, Lownie SP. Santyr B, et al. Neurosurg Focus. 2022 Aug;53(2):E3. doi: 10.3171/2022.5.FOCUS22188. Neurosurg Focus. 2022. PMID: 35916086
The mean overall score was significantly higher on the fifth attempt compared with the first attempt for all 3 live anastomotic modules (p < 0.001). Each module had a different improvement profile across the skills assessed. ...
The mean overall score was significantly higher on the fifth attempt compared with the first attempt for all 3 live anastomotic modules ( …
Early versus late surgical intervention or medical management for infective endocarditis: a systematic review and meta-analysis.
Anantha Narayanan M, Mahfood Haddad T, Kalil AC, Kanmanthareddy A, Suri RM, Mansour G, Destache CJ, Baskaran J, Mooss AN, Wichman T, Morrow L, Vivekanandan R. Anantha Narayanan M, et al. Heart. 2016 Jun 15;102(12):950-7. doi: 10.1136/heartjnl-2015-308589. Epub 2016 Feb 11. Heart. 2016. PMID: 26869640 Review.
OR of all-cause mortality for early surgery was 0.61 (95% CI 0.50 to 0.74, p<0.001) in unmatched groups and 0.41 (95% CI 0.31 to 0.54, p<0.001) in the propensity-matched groups (matched for baseline variables). ...In propensity-matched groups, the OR of mortal …
OR of all-cause mortality for early surgery was 0.61 (95% CI 0.50 to 0.74, p<0.001) in unmatched groups and 0.41 (95% CI 0.31 to 0 …
Personality profiles of self-immolators.
Kannapiran T, Haroon AE, Vivekanandan S, Arunagiri S. Kannapiran T, et al. Indian J Psychiatry. 1997 Jan;39(1):37-40. Indian J Psychiatry. 1997. PMID: 21584042 Free PMC article.
Hepatorenal syndrome: are we missing some prognostic factors?
Olivera-Martinez M, Sayles H, Vivekanandan R, D' Souza S, Florescu MC. Olivera-Martinez M, et al. Dig Dis Sci. 2012 Jan;57(1):210-4. doi: 10.1007/s10620-011-1861-1. Epub 2011 Aug 18. Dig Dis Sci. 2012. PMID: 21850494
Increased serum creatinine (p = 0.02) and urinary sodium 6-10 mEq/l (p = 0.027) at the initiation of therapy were prognostic factors for mortality. HRS treatment modalities (p = 0.73), use of dialysis (p = 0.56), dialysis modality (p = 0.35), us …
Increased serum creatinine (p = 0.02) and urinary sodium 6-10 mEq/l (p = 0.027) at the initiation of therapy were prognostic f …
Evaluation of the Efficacy of Guava Extract as an Antimicrobial Agent on Periodontal Pathogens.
Shetty YS, Shankarapillai R, Vivekanandan G, Shetty RM, Reddy CS, Reddy H, Mangalekar SB. Shetty YS, et al. J Contemp Dent Pract. 2018 Jun 1;19(6):690-697. J Contemp Dent Pract. 2018. PMID: 29959298
AIM: The present study was undertaken to assess the inhibitory effect of guava extracts on Porphyromonas gingivalis and Aggregatibacteractinomycetemcomitans, to assess the time-kill curve of P. gingivalis and A. actinomycetemcomitans, and to determine the antiproteolytic a …
AIM: The present study was undertaken to assess the inhibitory effect of guava extracts on Porphyromonas gingivalis and Aggregatibacteractin …
Risk of Bowel Obstruction in Patients Undergoing Neoadjuvant Chemotherapy for High-risk Colon Cancer: A Nested Case-control Matched Analysis of an International, Multi-centre, Randomised Controlled Trial (FOxTROT).
Glasbey J; FOxTROT Collaborating Group. Glasbey J, et al. Ann Surg. 2023 Nov 10. doi: 10.1097/SLA.0000000000006145. Online ahead of print. Ann Surg. 2023. PMID: 37947140
Patients underwent care in European hospitals including 88 UK, 7 Danish and 3 Swedish centres. There was more open surgery (65.4% vs. 38.0%, P =0.01) and a higher pR1 rate in obstructed patients (12.0% vs. 3.8%, P =0.004), but otherwise comparable postoperative outc …
Patients underwent care in European hospitals including 88 UK, 7 Danish and 3 Swedish centres. There was more open surgery (65.4% vs. 38.0%, …
COVID-19 Mortality and Therapeutics in Nebraska and Southwest Iowa during Early Pandemic.
Destache CJ, Ahmad F, Rajendrapasad S, Loranger A, Pruett W, Jagan N, Krajicek B, Schmidt D, Quimby D, Velagapudi M, Boldt D, Hayes S, Anthone J, Kessel B, Vivekanandan R. Destache CJ, et al. Pharmacy (Basel). 2022 Jun 24;10(4):69. doi: 10.3390/pharmacy10040069. Pharmacy (Basel). 2022. PMID: 35893707 Free PMC article.

Intubation, receipt of dexamethasone, African-American or Asian ethnicity, and being a patient from a nursing home were significantly associated with mortality (x2 = 86.36 (13) p < 0.0005). CONCLUSIONS: SARS-CoV-2 infected hospitalized patients had significant mortality

…
Intubation, receipt of dexamethasone, African-American or Asian ethnicity, and being a patient from a nursing home were significantly associ …
63 results